RT Journal Article
SR Electronic
T1 Factor V is an immune inhibitor that is expressed at increased levels in leukocytes of patients with severe Covid-19
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.01.14.21249801
DO 10.1101/2021.01.14.21249801
A1 Wang, Jun
A1 Kotagiri, Prasanti
A1 Lyons, Paul A
A1 Mescia, Federica
A1 Bergamaschi, Laura
A1 Turner, Lorinda
A1 Al-Lamki, Rafia S
A1 Morgan, Michael D
A1 Calero-Nieto, Fernando J
A1 Bach, Karsten
A1 Mende, Nicole
A1 Wilson, Nicola K
A1 Watts, Emily R
A1 ,
A1 Chinnery, Patrick F
A1 Kingston, Nathalie
A1 Papadia, Sofia
A1 Stirrups, Kathleen
A1 Walker, Neil
A1 Gupta, Ravindra K
A1 Toshner, Mark
A1 Weekes, Michael P
A1 Nathan, James A
A1 Walmsley, Sarah R
A1 Ouwehand, Willem H
A1 Kasanicki, Mary
A1 Göttgens, Berthold
A1 Marioni, John C
A1 Smith, Kenneth GC
A1 Pober, Jordan S
A1 Bradley, John R
YR 2021
UL http://medrxiv.org/content/early/2021/01/15/2021.01.14.21249801.abstract
AB Severe Covid-19 is associated with elevated plasma Factor V (FV) and increased risk of thromboembolism. We report that neutrophils, T regulatory cells (Tregs), and monocytes from patients with severe Covid-19 express FV, and expression correlates with T cell lymphopenia. In vitro full length FV, but not FV activated by thrombin cleavage, suppresses T cell proliferation. Increased and prolonged FV expression by cells of the innate and adaptive immune systems may contribute to lymphopenia in severe Covid-19. Activation by thrombin destroys the immunosuppressive properties of FV. Anticoagulation in Covid-19 patients may have the unintended consequence of suppressing the adaptive immune system.Competing Interest StatementRKG acts as a consultant for UMOVIS labFunding StatementThe work was funded by awards from NIHR to the NIHR BioResource and the NIHR Cambridge Biomedical Research Centre, Evelyn Trust, UKRI/NIHR funding through the UK Coronavirus Immunology Consortium (UK-CIC) and a CSO award (COV/DUN/20/01). KGCS holds a Wellcome Trust Investigator award. BG holds an award from the Aging Biology Foundation Europe to BG. RKG holds a Wellcome Senior Fellowship (WT108082AIA). PK is supported by the Australian and New Zealand Society of Nephrology and the Royal Australasian College of Physicians. SRW holds a Wellcome Trust Senior Clinical Fellowship (209220). ERW holds a Wellcome Clinical Training Fellowship award (108717/Z/15/Z). NM was supported by a DFG Research Fellowship. PFC is a Wellcome Trust Principal Research Fellow (212219/Z/18/Z), and a NIHR Senior Investigator, and receives support from the Medical Research Council (MRC) Mitochondrial Biology Unit, the MRC International Centre for Genomic Medicine in Neuromuscular Disease, the Leverhulme Trust, a MRC research grant, and an Alzheimer's Society Project Grant. JAN holds a Wellcome Trust Senior Research Fellowship (215477/Z/19/Z).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Cambridge Central National Research Ethics Committee - reference 17/EE/0025/AM23All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe NIHR BioResource makes data available to researchers through a Data Access Application process described at: https://bioresource.nihr.ac.uk/using-our-bioresource/academic-and-clinical-researchers/apply-for-bioresource-data/